Martin Latterich,
Chief Scientific Officer,
Bioscale
Martin Latterich, PhD serves as the Chief Scientific Officer of BioScale. Dr. Latterich has held senior management positions at several biotechnology companies, including Diversa and Illumina, where he headed the proteomics initiatives. He has made significant contributions to the field of cell biology, clinical biomarker discovery, proteomics and genomics. Among his recent discoveries are biomarkers for cancer, respiratory disease and neurodegenerative disorders. Dr Latterich has edited one book on RNAi, is author on over 32 publications in leading scientific journals and is listed on numerous patent applications. Martin is Editor-in-Chief of the scientific journal Proteome Science. He has served on several national and international study sections. He was a postdoctoral fellow in molecular and cell biology in the laboratory of Dr. Randy Schekman at the HHMI and University of California, Berkeley. Dr. Latterich earned his Ph.D. in cell biology and a B.Sc. in biochemistry and molecular biology from Durham University, UK.
Biomarker-driven Translational Medicine
Thursday, 6 June 2013 at 17:00
Add to Calendar ▼2013-06-06 17:00:002013-06-06 18:00:00Europe/LondonBiomarker-driven Translational MedicineTranslational Medicine Summit in HamburgHamburgSELECTBIOenquiries@selectbiosciences.com
Biomarkers are molecules that provide information about a biological state in cells, tissues and entire organisms. A key goal of the translational medicine field is the identification and measurement of biomarkers that describe a disease or a response to a treatment. The biomarker field has rapidly evolved over the past decade, away from the use of descriptive or surrogate markers, to markers that are mechanistically linked to disease or that indicate treatment options and efficacy of treatment. There are numerous emerging examples of biomarker successes in translational research, such as pharmacodynamic markers and markers that provide actionable treatment options, often at an individual level.
The modern translational biomarker laboratory is characterized by having to develop a marker or panel of markers common to both patients, cellular and animal models of disease. These panels can now consist of mixed classes or markers, such a genomic, RNA protein and metabolite, making it harder to develop a universal analytical platforms as opposed to optimized assays to quantify these biomarkers on different platforms. In addition to technological challenges, such as matrix interference in immune assays and mRNA stability in blood and tissue, there are conceptual challenges that urge a rethinking of regulatory paradigms. For example, why do we have to structure clinical trials for an anti-cancer drug based on morphologically defined tumors using criteria that arose many years ago and reflect a rather poor understanding of tumor biology, or could we actually structure trials based on an actionable biomarker defining the tumor, irrespective of tumor morphology and location. The next decade should prove both interesting and conceptually challenging for the translational researcher and clinician.
Add to Calendar ▼2013-06-06 00:00:002013-06-07 00:00:00Europe/LondonTranslational Medicine SummitTranslational Medicine Summit in HamburgHamburgSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2013-06-06 17:00:002013-06-06 18:00:00Europe/LondonBiomarker-driven Translational MedicineTranslational Medicine Summit in HamburgHamburgSELECTBIOenquiries@selectbiosciences.com
